EMA Authorised: Augtyro (repotrectinib) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

EMA authorised Augtyro (repotrectinib) for non-small cell lung cancer under a conditional marketing authorization. The marketing authorization holder is Bristol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AUGTYRO (repotrectinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Cancer. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 13/01/2025. Conditional approval